Key facts
- Ensoma’s last known valuation is $280.0M (May 2023).
- It has raised $258.0M across 3 recorded rounds; the latest was Later Stage VC (Series B1) ($53.0M) in Sep 2025.
- Notable investors include Viking Global Investors, F-Prime Capital, Alexandria Venture Investments, Gates Foundation, Qatar Investment Authority — 21 tracked in total.
- Ensoma has filed 3 Form Ds with the SEC since 2021, most recently May 2023 ($129.0M sold to 22 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Ensoma
Funding rounds
3 roundsAbout Ensoma
Operator of a biotech company intended to develop a genomic medicine in vivo approach to engineer any or all blood and immune cells to cure diseases. The company focuses on engineered vectors that permit to delivery of gene modification technologies directly to stem cells or the various cell types that arise from these cells, such as T cells, B cells, and myeloid cells, without the need for stem cell collection or prior conditioning, which can be toxic to patients, enabling health professionals to have access to genomic medicines that can be delivered in a single injection.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2019
- Employees
- 67
- Website
- ensoma.com/
- Ownership
- Privately Held (backing)
Ensoma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ensoma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ensoma in its N-PORT filings yet. We sweep new filings monthly.